Merck & Co. (MRK) : Bennicas Associates reduced its stake in Merck & Co. by 4.33% during the most recent quarter end. The investment management company now holds a total of 57,408 shares of Merck & Co. which is valued at $3,257,330 after selling 2,600 shares in Merck & Co. , the firm said in a disclosure report filed with the SEC on Apr 18, 2016.Merck & Co. makes up approximately 3.03% of Bennicas Associates’s portfolio.
Merck & Co. opened for trading at $56.69 and hit $57.03 on the upside on Friday, eventually ending the session at $56.74, with a gain of 0.25% or 0.14 points. The heightened volatility saw the trading volume jump to 70,93,479 shares. Company has a market cap of $157,468 M.
Other Hedge Funds, Including , Joel Isaacson reduced its stake in MRK by selling 479 shares or 2.76% in the most recent quarter. The Hedge Fund company now holds 16,859 shares of MRK which is valued at $956,580. Merck & Co. makes up approx 0.21% of Joel Isaacson’s portfolio.Btr Capital Management Inc reduced its stake in MRK by selling 1,765 shares or 1.93% in the most recent quarter. The Hedge Fund company now holds 89,511 shares of MRK which is valued at $5,025,148. Merck & Co. makes up approx 1.15% of Btr Capital Management Inc’s portfolio.Osborne Partners Capital Management reduced its stake in MRK by selling 300 shares or 1.87% in the most recent quarter. The Hedge Fund company now holds 15,708 shares of MRK which is valued at $881,847. Merck & Co. makes up approx 0.13% of Osborne Partners Capital Management’s portfolio.Tufton Capital Management boosted its stake in MRK in the latest quarter, The investment management firm added 169 additional shares and now holds a total of 194,718 shares of Merck & Co. which is valued at $10,931,469. Merck & Co. makes up approx 2.71% of Tufton Capital Management’s portfolio.E&g Advisors Lp reduced its stake in MRK by selling 1,595 shares or 5.47% in the most recent quarter. The Hedge Fund company now holds 27,555 shares of MRK which is valued at $1,546,938. Merck & Co. makes up approx 1.00% of E&g Advisors Lp’s portfolio.
On the company’s financial health, Merck & Co. reported $0.93 EPS for the quarter, beating the analyst consensus estimate by $ 0.02 according to the earnings call on Feb 3, 2016. Analyst had a consensus of $0.91. The company had revenue of $10215.00 million for the quarter, compared to analysts expectations of $10355.20 million. The company’s revenue was down -2.5 % compared to the same quarter last year.During the same quarter in the previous year, the company posted $0.87 EPS.
Many Wall Street Analysts have commented on Merck & Co.. Societe Generale Initiated Merck & Co. on Apr 6, 2016 to “Buy”, Price Target of the shares are set at $80.Merck & Co. was Downgraded by BofA/Merrill to ” Neutral” on Jan 27, 2016.
Merck & Co. Inc. is a global health care company. The Company offers health solutions through its prescription medicines vaccines biologic therapies and animal health products which it markets directly and through its joint ventures. The Companys Pharmaceutical segment includes human health pharmaceutical and vaccine products marketed either directly by the Company or through joint ventures. Human health pharmaceutical products consist of therapeutic and preventive agents generally sold by prescription for the treatment of human disorders. The Company sells these human health pharmaceutical products primarily to drug wholesalers and retailers hospitals government agencies and managed health care providers. The Animal Health segment discovers develops manufactures and markets animal health products including vaccines. The Companys animal health products are sold to veterinarians distributors and animal producers.